中国放射性药物制备的现状及展望
|
摘要
介绍我国放射性药物制备发展的初级、起步和快速发展三个阶段,从企业和医院的放射性药物生产和制备两个方面介绍目前放射性药物制备的现况,针对存在的问题,提出措施和建议。基于PSMA的放射性药物用于肿瘤诊断和治疗有可能成为热点,而中枢神经退行性疾病中,Tau蛋白显像剂的临床应用价值则更大。
The histrotry of radiopharmaceuticals development in China could be classified into three stages: the begining stage, the settelement stage and the rapid development stage. The current status of the preparation of radiopharmaceuticals from enterprises and hospitals was reviewed, and the measures and suggestions were put to resolve the problem which occurred in recent radiopharmaceuticals development. The research of development of PSMA based diagnostic and therapeutic radiopharmaceuticals would be hot spot. The Tau protein imaging will be more valuable in degenerative diseases of CNS.
The histrotry of radiopharmaceuticals development in China could be classified into three stages: the begining stage, the settelement stage and the rapid development stage. The current status of the preparation of radiopharmaceuticals from enterprises and hospitals was reviewed, and the measures and suggestions were put to resolve the problem which occurred in recent radiopharmaceuticals development. The research of development of PSMA based diagnostic and therapeutic radiopharmaceuticals would be hot spot. The Tau protein imaging will be more valuable in degenerative diseases of CNS.
引文
[1] 潘俊男,程作用.放射免疫治疗中单克隆抗体药物研究现状[J].同位素,2013,26(2):122-128.
[2] 尤林怡,郭志德,张现忠.诊断用放射性药物研究现状与展望[J].同位素,2017,30(4):292-306.
[3] 田佳乐,贾红梅.99mTc-放射性药物的现状和展望[J].同位素,2018,31(3):143-156.
[4] 盛安陵.着眼长远引领中国放药发展[J].中国核工业,2016,6:27-29.
[5] 李金锋,欧阳涛,王雪鹃,等.新型示踪剂99mTc-利妥昔用于原发性乳腺癌前哨淋巴结活检的初步研究[J].中华外科杂志,2006,44(9):600-602.
[6] 李家敏,孙启银,孙爱君,等.18F-FDG PET在癫痫灶定位诊断中的初步应用[J].中华核医学杂志,1996,16(2):136-137.
[7] 边艳珠.帕金森病的实验和临床神经功能影像学研究[D].石家庄:河北医科大学,2003.
[8] 吴春英.正电子发射断层(PET)基础与临床研究:短半衰期正电子放射性药物的研究[D].上海:复旦大学,2003.
[9] 李靖轩.O-(2-[18F]氟乙基)-L-酪氨酸的研制[D].北京:中国原子能科学研究院,2004.
[10] 张清.11C-胆碱PET在肺癌诊断与分期中的应用研究[D].北京:中国人民解放军军医进修学院,2005.
[11] 18F-FMISO PET在肺癌动物模型中的实验研究[D].北京:中国人民解放军军医进修学院,2006.
[12] 柳曦.18F-FLT PET在肺癌中的动物实验和临床研究[D].北京:中国人民解放军军医进修学院,2006.
[13] 董孟杰.正电子发射断层(PET)基础与临床研究[D].上海:复旦大学,2006.
[14] 党永红.F-18标记的酪氨酸类化合物的合成、动物实验及临床实验研究[D].北京:中国协和医科大学,2002.
[15] 赵军.正电子发射断层(PET)基础与临床研究:帕金森病(PD)PET受体显像实验与临床研究[D].上海:复旦大学,2003.
[16] 郭喆.阿尔茨海默病正电子成像基础与临床研究:老年斑在体显像[D].北京:中国人民解放军军医进修学院,2005.
[17] 核医学/放射性医药品的欧洲市场预测[M/OL].https://www.giichinese.com.cn/report/mama268459-european-nuclear-medicine-radiopharmaceuticals.html,2020.
[18] 霍力,党永红,付喆,等.碳-11乙酸盐正电子断层显像临床应用[J].中国医学影像学杂志,2010,18(4):293-300.
[19] 吴湖炳,王全师,王明芳,等.11C-胆碱显像在18F-FDG显像诊断不明确肝占位病变患者中的应用[J].中华核医学杂志,2010,30(4):217-221.
[20] 王瑞民,郭喆,杨晖,等.帕金森病与多系统萎缩患者多模态正电子成像统计参数图对比分析[J].中华神经科杂志,2017,50(7):501-505.
[21] 2018年中国核医学现状普查结果[M/OL].http://www.sohu.com/a/253106206_655053,2018.
[22] 李欣.99mTc-HER2亲合体的合成及在乳腺癌中的初步临床应用[D].北京:协和医科大学,2016.
[23] Li Nan,Wang Xuejuan,Lin Baohe,et al.Clinical evaluation of 99mTc-Rituximab for sentinel lymph node mapping in breast cancer patients[J].J Nucl Med,2016,57(8):1 214-1 220.
[24] 陈明龙.99mTc-RGD-BBN SPECT显像在BI-RADS 4C级乳腺肿瘤中的应用价值[D].长春:吉林大学,2016.
[25] 胡四龙,许晓平,朱耀宿,等.99mTc标记PSMA小分子抑制剂靶向前列腺癌分子影像初步临床研究[J] .中国癌症杂志,2016,26(7):608-615.
[26] 郭喆.Aβ蛋白PET显像用于AD诊断和疗效监测的实验研究[D].北京:中国人民解放军军医进修学院,2008.
[27] 王伟君.18F-ML-10 PET-CT细胞凋亡显像早期评价经cyberknife治疗颅脑肿瘤的疗效及[D].北京:中国人民解放军军医进修学院,2015.
[28] 崔璨.新型PET显像剂68Ga-HBED-CC-Lys-CO-Glu用于前列腺癌靶向显像的研究[D].南京:南京医科大学,2016.
[29] 常燕.18F-AV-45和18F-FDG PET联合脑显像在阿尔茨海默病中的诊断价值[D].乌鲁木齐:新疆医科大学,2018.
[30] 高之晔.18F-FCH联合18F-FDG PET/CT显像在肝细胞肝癌中的应用价值[D].郑州:郑州大学,2018.
[31] 王珍珍.18F-FMISO PET/CT显像在非小细胞肺癌放射治疗中的临床应用价值[D].郑州:郑州大学,2016.
[32] 张会.探索18F-RGD PET/CT对新诊断胶质母细胞瘤术后同步放化疗敏感性的预测价值[D].济南:济南大学,2016.
[33] 王玲.68Ga枸橼酸的合成及在炎症性肠病中的初步临床应用[D].北京:北京协和医学院,2015.
[34] 朱湘,王英曼,宋秀宇,等.18F-FES PET/CT检查对乳腺癌诊断及疗效评估的价值分析[J].山东肿瘤,2016,56(32):19-22.
[35] 富丽萍,张锦明,王盼,等.阿尔茨海默病斑块显像:新型放射性示踪剂18F-W372在体试验初探[J].军医进修学院学报,2011,33(1):23-26.
[36] 鲍伟奇.GABAA/BZ受体PET显像剂11C-FMZ的放射性药物制备及在严重脑外伤患者大脑神经元损伤的评价[D].上海:复旦大学,2013.
[37] 冼文彪,史新冲,张祥松,等.[11C]CFT脑多巴胺转运体PET显像对帕金森病诊断和严重程度评估的应用[J].中国神经精神疾病杂志,2014,40(8):474-78.
[38] 尚琨,乔洪文,卢洁,等.18F-FDG及18F-FP-DTBZ双示踪PET/CT显像诊断帕金森病[J].中国医学影像技术,2018,34(11):1 615-1 620.
[39] 付华平,张晓军,麻广宇,等.国产氟多功能模块自动化合成18F-6-氟-L-DOPA及其临床初步应用[J].同位素,2018,31(5):298-303.
[40] 张晓军,付华平,李云钢,等.18F-DCFPyL的制备和初步临床应用[J].同位素,2018,31(5):291-297.
[41] Guo Xiaoyi ,Zhu Hua,Zhou Nina,et al.Non-invasive detection of HER2 expression in gastric cancer by 64Cu-NOTA-trastuzumab in PDX mouse model and in patients[J].Mol Pharm ,2018,15(11):5 174-5 182.
[42] Xu X,Zhu H,Liu F,et al.Imaging brain metastasis patients with 18F-(2S,4R)-4-fluoroglutamine[J] .Clin Nucl Med,2018,43(11):e392-e399 .
[43] Li L,Ma L,Shang D,et al.Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response[J].Eur J Nucl Med Mol Imaging,2018,In printing.
[44] Meng Xue,Loo Billy W,Ma Li,et al.Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI:a pilot study[J].J Nucl Med,2011,52(10):1 573-1 579.
[45] Li L,Wei Y,Huang Y,et al.To explore a representative hypoxic parameter to predict the treatment response and prognosis obtained by [18F]FMISO-PET in patients with non-small cell lung cancer[J].Mol Imaging Biol,2018,20(6):1 061-1 067.
[46] Gong Chengcheng,Yang Zhongyi,Sun Yifei,et al.A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel[J].Sci Rep,2017,7(1):6 584 .
[47] Wang R,Zhu H,Chen Y,et al.Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT[J].Hematol Oncol,2014,32(3):126-132 .
[48] Zhang B,He Q,Shi X,et al.Recurrent scapular metastasis from hepatoblastoma shown on FDG PET/CT and F-DOPA PET/CT[J].Clin Nucl Med,2017,42(10):e449-e451.
[49] Zhang Jingliang,Shao Shuai ,Wu Peng,et al.Diagnostic performance of 68Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy:comparison with cancer-predicting nomograms[J].Eur J Nucl Med Mol Imaging,2019,46(4):908-920.
[50] 刘大亮,李国权,陈玲,等.68Ga-PSMA-617 PET/CT与多参数MRI诊断前列腺癌的对比研究[J] .中华核医学与分子影像杂志,2019,39(2):72-76 .
[51] 秦露平,吕杰,李名钊,等.68Ga-PSMA-11 PET/CT半定量指标对前列腺良恶性病变鉴别诊断的价值[J].中华核医学与分子影像杂志,2019,39(2):67-71.
[52] 卜婷,张川,臧士明,等.177Lu-PSMA-617治疗转移性前列腺癌的安全性和疗效[J].中华核医学与分子影像杂志,2019,39(2):81-85.
[53] Demirci,Emre,Ocak,et al.68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma[J].Eur J Nucl Med Mol Imaging,2014,41(7):1 461-1 462.
[54] Sathekge,Mike ,Modiselle ,et al .68Ga-PSMA imaging of metastatic breast cancer[J] .Eur J Nucl Med Mol Imaging,2015,42(9):1 482-1 483.
[55] Kesler M,Levine C,Hershkovitz D,et al.Sapir 68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma:A prospective pilot study[J].J Nucl Med,2018:jnumed.118.214833.
[56] Sasikumar A ,Kashyap R,Joy A,et al.Utility of 68Ga-PSMA-11 PET/CT in imaging of glioma-A pilot study[J].Clin Nucl Med,SEP 2018,43(9):E304-E309.
[57] Villemagne V L.Selective Tau imaging:der stand der dinge[J].J Nucl Med,2018,59(2):175-176.
[58] 罗亚平,潘青青,朱朝晖,等.琥珀酰明胶注射液降低肾脏摄取68Ga-exendin-4的随机对照研究[J].标记免疫分析与临床,2018,25(9):1 253-1 258.
[59] Zang J,Fan X,Wang H,et al.First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer[J].Eur J Nucl Med Mol Imaging,2019,49(1):148-158.
[2] 尤林怡,郭志德,张现忠.诊断用放射性药物研究现状与展望[J].同位素,2017,30(4):292-306.
[3] 田佳乐,贾红梅.99mTc-放射性药物的现状和展望[J].同位素,2018,31(3):143-156.
[4] 盛安陵.着眼长远引领中国放药发展[J].中国核工业,2016,6:27-29.
[5] 李金锋,欧阳涛,王雪鹃,等.新型示踪剂99mTc-利妥昔用于原发性乳腺癌前哨淋巴结活检的初步研究[J].中华外科杂志,2006,44(9):600-602.
[6] 李家敏,孙启银,孙爱君,等.18F-FDG PET在癫痫灶定位诊断中的初步应用[J].中华核医学杂志,1996,16(2):136-137.
[7] 边艳珠.帕金森病的实验和临床神经功能影像学研究[D].石家庄:河北医科大学,2003.
[8] 吴春英.正电子发射断层(PET)基础与临床研究:短半衰期正电子放射性药物的研究[D].上海:复旦大学,2003.
[9] 李靖轩.O-(2-[18F]氟乙基)-L-酪氨酸的研制[D].北京:中国原子能科学研究院,2004.
[10] 张清.11C-胆碱PET在肺癌诊断与分期中的应用研究[D].北京:中国人民解放军军医进修学院,2005.
[11] 18F-FMISO PET在肺癌动物模型中的实验研究[D].北京:中国人民解放军军医进修学院,2006.
[12] 柳曦.18F-FLT PET在肺癌中的动物实验和临床研究[D].北京:中国人民解放军军医进修学院,2006.
[13] 董孟杰.正电子发射断层(PET)基础与临床研究[D].上海:复旦大学,2006.
[14] 党永红.F-18标记的酪氨酸类化合物的合成、动物实验及临床实验研究[D].北京:中国协和医科大学,2002.
[15] 赵军.正电子发射断层(PET)基础与临床研究:帕金森病(PD)PET受体显像实验与临床研究[D].上海:复旦大学,2003.
[16] 郭喆.阿尔茨海默病正电子成像基础与临床研究:老年斑在体显像[D].北京:中国人民解放军军医进修学院,2005.
[17] 核医学/放射性医药品的欧洲市场预测[M/OL].https://www.giichinese.com.cn/report/mama268459-european-nuclear-medicine-radiopharmaceuticals.html,2020.
[18] 霍力,党永红,付喆,等.碳-11乙酸盐正电子断层显像临床应用[J].中国医学影像学杂志,2010,18(4):293-300.
[19] 吴湖炳,王全师,王明芳,等.11C-胆碱显像在18F-FDG显像诊断不明确肝占位病变患者中的应用[J].中华核医学杂志,2010,30(4):217-221.
[20] 王瑞民,郭喆,杨晖,等.帕金森病与多系统萎缩患者多模态正电子成像统计参数图对比分析[J].中华神经科杂志,2017,50(7):501-505.
[21] 2018年中国核医学现状普查结果[M/OL].http://www.sohu.com/a/253106206_655053,2018.
[22] 李欣.99mTc-HER2亲合体的合成及在乳腺癌中的初步临床应用[D].北京:协和医科大学,2016.
[23] Li Nan,Wang Xuejuan,Lin Baohe,et al.Clinical evaluation of 99mTc-Rituximab for sentinel lymph node mapping in breast cancer patients[J].J Nucl Med,2016,57(8):1 214-1 220.
[24] 陈明龙.99mTc-RGD-BBN SPECT显像在BI-RADS 4C级乳腺肿瘤中的应用价值[D].长春:吉林大学,2016.
[25] 胡四龙,许晓平,朱耀宿,等.99mTc标记PSMA小分子抑制剂靶向前列腺癌分子影像初步临床研究[J] .中国癌症杂志,2016,26(7):608-615.
[26] 郭喆.Aβ蛋白PET显像用于AD诊断和疗效监测的实验研究[D].北京:中国人民解放军军医进修学院,2008.
[27] 王伟君.18F-ML-10 PET-CT细胞凋亡显像早期评价经cyberknife治疗颅脑肿瘤的疗效及[D].北京:中国人民解放军军医进修学院,2015.
[28] 崔璨.新型PET显像剂68Ga-HBED-CC-Lys-CO-Glu用于前列腺癌靶向显像的研究[D].南京:南京医科大学,2016.
[29] 常燕.18F-AV-45和18F-FDG PET联合脑显像在阿尔茨海默病中的诊断价值[D].乌鲁木齐:新疆医科大学,2018.
[30] 高之晔.18F-FCH联合18F-FDG PET/CT显像在肝细胞肝癌中的应用价值[D].郑州:郑州大学,2018.
[31] 王珍珍.18F-FMISO PET/CT显像在非小细胞肺癌放射治疗中的临床应用价值[D].郑州:郑州大学,2016.
[32] 张会.探索18F-RGD PET/CT对新诊断胶质母细胞瘤术后同步放化疗敏感性的预测价值[D].济南:济南大学,2016.
[33] 王玲.68Ga枸橼酸的合成及在炎症性肠病中的初步临床应用[D].北京:北京协和医学院,2015.
[34] 朱湘,王英曼,宋秀宇,等.18F-FES PET/CT检查对乳腺癌诊断及疗效评估的价值分析[J].山东肿瘤,2016,56(32):19-22.
[35] 富丽萍,张锦明,王盼,等.阿尔茨海默病斑块显像:新型放射性示踪剂18F-W372在体试验初探[J].军医进修学院学报,2011,33(1):23-26.
[36] 鲍伟奇.GABAA/BZ受体PET显像剂11C-FMZ的放射性药物制备及在严重脑外伤患者大脑神经元损伤的评价[D].上海:复旦大学,2013.
[37] 冼文彪,史新冲,张祥松,等.[11C]CFT脑多巴胺转运体PET显像对帕金森病诊断和严重程度评估的应用[J].中国神经精神疾病杂志,2014,40(8):474-78.
[38] 尚琨,乔洪文,卢洁,等.18F-FDG及18F-FP-DTBZ双示踪PET/CT显像诊断帕金森病[J].中国医学影像技术,2018,34(11):1 615-1 620.
[39] 付华平,张晓军,麻广宇,等.国产氟多功能模块自动化合成18F-6-氟-L-DOPA及其临床初步应用[J].同位素,2018,31(5):298-303.
[40] 张晓军,付华平,李云钢,等.18F-DCFPyL的制备和初步临床应用[J].同位素,2018,31(5):291-297.
[41] Guo Xiaoyi ,Zhu Hua,Zhou Nina,et al.Non-invasive detection of HER2 expression in gastric cancer by 64Cu-NOTA-trastuzumab in PDX mouse model and in patients[J].Mol Pharm ,2018,15(11):5 174-5 182.
[42] Xu X,Zhu H,Liu F,et al.Imaging brain metastasis patients with 18F-(2S,4R)-4-fluoroglutamine[J] .Clin Nucl Med,2018,43(11):e392-e399 .
[43] Li L,Ma L,Shang D,et al.Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response[J].Eur J Nucl Med Mol Imaging,2018,In printing.
[44] Meng Xue,Loo Billy W,Ma Li,et al.Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI:a pilot study[J].J Nucl Med,2011,52(10):1 573-1 579.
[45] Li L,Wei Y,Huang Y,et al.To explore a representative hypoxic parameter to predict the treatment response and prognosis obtained by [18F]FMISO-PET in patients with non-small cell lung cancer[J].Mol Imaging Biol,2018,20(6):1 061-1 067.
[46] Gong Chengcheng,Yang Zhongyi,Sun Yifei,et al.A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel[J].Sci Rep,2017,7(1):6 584 .
[47] Wang R,Zhu H,Chen Y,et al.Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT[J].Hematol Oncol,2014,32(3):126-132 .
[48] Zhang B,He Q,Shi X,et al.Recurrent scapular metastasis from hepatoblastoma shown on FDG PET/CT and F-DOPA PET/CT[J].Clin Nucl Med,2017,42(10):e449-e451.
[49] Zhang Jingliang,Shao Shuai ,Wu Peng,et al.Diagnostic performance of 68Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy:comparison with cancer-predicting nomograms[J].Eur J Nucl Med Mol Imaging,2019,46(4):908-920.
[50] 刘大亮,李国权,陈玲,等.68Ga-PSMA-617 PET/CT与多参数MRI诊断前列腺癌的对比研究[J] .中华核医学与分子影像杂志,2019,39(2):72-76 .
[51] 秦露平,吕杰,李名钊,等.68Ga-PSMA-11 PET/CT半定量指标对前列腺良恶性病变鉴别诊断的价值[J].中华核医学与分子影像杂志,2019,39(2):67-71.
[52] 卜婷,张川,臧士明,等.177Lu-PSMA-617治疗转移性前列腺癌的安全性和疗效[J].中华核医学与分子影像杂志,2019,39(2):81-85.
[53] Demirci,Emre,Ocak,et al.68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma[J].Eur J Nucl Med Mol Imaging,2014,41(7):1 461-1 462.
[54] Sathekge,Mike ,Modiselle ,et al .68Ga-PSMA imaging of metastatic breast cancer[J] .Eur J Nucl Med Mol Imaging,2015,42(9):1 482-1 483.
[55] Kesler M,Levine C,Hershkovitz D,et al.Sapir 68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma:A prospective pilot study[J].J Nucl Med,2018:jnumed.118.214833.
[56] Sasikumar A ,Kashyap R,Joy A,et al.Utility of 68Ga-PSMA-11 PET/CT in imaging of glioma-A pilot study[J].Clin Nucl Med,SEP 2018,43(9):E304-E309.
[57] Villemagne V L.Selective Tau imaging:der stand der dinge[J].J Nucl Med,2018,59(2):175-176.
[58] 罗亚平,潘青青,朱朝晖,等.琥珀酰明胶注射液降低肾脏摄取68Ga-exendin-4的随机对照研究[J].标记免疫分析与临床,2018,25(9):1 253-1 258.
[59] Zang J,Fan X,Wang H,et al.First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer[J].Eur J Nucl Med Mol Imaging,2019,49(1):148-158.